Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 1, 2022Following Discussion with the FDA, Karyopharm Plans to Initiate a New Placebo-Controlled Randomized Study of Selinexor in the Advanced or Recurrent Endometrial Cancer p53 Wild-Type Population to Support a Future sNDA Submission as the Current Topline Data from the SIENDO Study are Unlikely to Support an sNDA Approval
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today provided an update on its discussions with the U.S. Food and Drug...
-
Feb 28, 2022
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company approved the grant of stock options to...
-
Feb 22, 2022− Patricia Judson, M.D., Formerly of GSK and AstraZeneca, Appointed as Senior Vice President of Medical Strategy -
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced changes to its clinical leadership team, including the...
-
Feb 8, 2022-- XPOVIO® Achieves Net Product Revenue of $98.4 Million for Full Year 2021; Company Provides Full Year 2022 XPOVIO Net Product Revenue Guidance of $135 to $145 Million --
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm," the "Company," "we" and "our"), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial...
-
Feb 8, 2022- Selinexor Demonstrates Statistically Significant 50% Improvement in Median Progression-Free Survival Compared to Placebo (Hazard Ratio of 0.70; p=0.0486) -
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced positive top-line results from the Phase 3 Selinexor In...